Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia

(2011) Sébastien Gallien et al.   AIDS

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

(2011) Benjamin Young et al.   ANTIVIRAL THERAPY

Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy

(2011) Babafemi Taiwo et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

(2011) Linda Wittkop et al.   LANCET INFECTIOUS DISEASES

Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care

(2011) Emily Suzanne Brouwer et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors

(2010) Charlotte Charpentier et al.   AIDS

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

(2010) Jia Liu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification

(2010) Celine S. Yan et al.   JOURNAL OF CLINICAL VIROLOGY

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction

(2010) Massimiliano Fabbiani et al.   PHARMACOLOGICAL RESEARCH

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel

(2008) Martin S. Hirsch et al.   CLINICAL INFECTIOUS DISEASES

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

(2008) Sharon A. Riddler et al.   NEW ENGLAND JOURNAL OF MEDICINE